UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Interplay between Immune Checkpoint Proteins and Cellular Metabolism

Cancer research (Chicago, Ill.), 2017-03, Vol.77 (6), p.1245-1249

2017

Volltextzugriff (PDF)

The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing

PLoS neglected tropical diseases, 2011-08, Vol.5 (8), p.e1297

2011

Volltextzugriff (PDF)

Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response

Biology (Basel, Switzerland), 2021-04, Vol.10 (5), p.385

2021

Volltextzugriff (PDF)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Communications medicine, 2022-08, Vol.2 (1), p.106-9, Article 106

2022

Volltextzugriff (PDF)

Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α

Cancer research (Chicago, Ill.), 2016-04, Vol.76 (8), p.2231-2242

2016

Volltextzugriff (PDF)

Analysis of the COVID-19 Vaccine Development Process: an Exploratory Study of Accelerating Factors and Innovative Environments

Journal of pharmaceutical innovation, 2021-02, Vol.17 (2), p.555-571

2021

Volltextzugriff (PDF)

Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?

Gynecologic oncology, 2017-05, Vol.145 (2), p.329-333

2017

Volltextzugriff (PDF)

The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19

Journal of pharmaceutical innovation, 2023-09, Vol.18 (3), p.1194-1212

2023

Volltextzugriff (PDF)

Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling

Oncotarget, 2017-09, Vol.8 (41), p.69264-69280

2017

Volltextzugriff (PDF)

Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin

Cancer prevention research (Philadelphia, Pa.), 2021-11, Vol.14 (11), p.995-1008

2021

Volltextzugriff (PDF)

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer

Journal of ovarian research, 2022-11, Vol.15 (1), p.120-17, Article 120

2022

Volltextzugriff (PDF)

Prospects and Trends in the Brazilian Market for Biologically Sourced Products

Journal of technology management & innovation, 2012-10, Vol.7 (3), p.44-56

2012

Volltextzugriff (PDF)

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

Vaccines (Basel), 2021-08, Vol.9 (8), p.894

2021

Volltextzugriff (PDF)

DNA damage measurements within tissue samples with Repair Assisted Damage Detection (RADD)

Current research in biotechnology, 2019-11, Vol.1, p.78-86

2019

Volltextzugriff (PDF)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Communications medicine, 2023-05, Vol.3 (1), p.63-1, Article 63

2023

Volltextzugriff (PDF)

RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance

Oncogene, 2017-11, Vol.36 (48), p.6680-6690

2017

Volltextzugriff (PDF)

Associations between DNA damage and PDL‐1 expression in ovarian cancer, a potential biomarker for clinical response

The FASEB journal, 2021-05, Vol.35 (S1), p.n/a, Article fasebj.2021.35.S1.05041

2021

Volltextzugriff (PDF)

A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.249-249

2023

Volltextzugriff (PDF)

The novel NSAID-derivative, MCI-030, prevents ovarian cancer in the egg-laying hen by increasing tumor cell apoptosis and decreasing beta-catenin and MAPK oncogenic signaling

Gynecologic oncology, 2021-08, Vol.162, p.S301-S302

2021

Volltextzugriff (PDF)

Abstract B057: Racial disparity research in ovarian cancer: Evaluating race definition in differential gene expression

Cancer epidemiology, biomarkers & prevention, 2020-06, Vol.29 (6_Supplement_1), p.B057-B057

2020

Volltextzugriff (PDF)

Abstract 1213: PDE10A as a novel target to suppress Wnt/β-catenin signaling and other oncogenic pathways in ovarian cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1213-1213

2021

Volltextzugriff (PDF)

Abstract B31: Tumor-intrinsic B7-H3 regulates drug resistance, metabolism, and pathogenesis in ovarian cancer

Clinical cancer research, 2018-08, Vol.24 (15_Supplement), p.B31-B31

2018

Volltextzugriff (PDF)

Abstract POSTER-BIOL-1336: Investigating the role of phosphodiesterase 10A as a novel target in ovarian cancer

Clinical cancer research, 2015-08, Vol.21 (16_Supplement), p.POSTER-BIOL-1336-POSTER-BIOL-1336

2015

Volltextzugriff (PDF)

Abstract 5165: Novel RAS inhibitors DC070-547 and ADT-006 potently and selectively inhibit the growth of pancreatic tumor cells harboring constitutively activated RAS by blocking RAS-effector binding and signaling

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5165-5165

2017

Volltextzugriff (PDF)

Abstract 1937: Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1937-1937

2018

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaMultidisciplinary Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(75)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Interplay between Immune Checkpoint Proteins and Cellular Metabolism

The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing

Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α

Analysis of the COVID-19 Vaccine Development Process: an Exploratory Study of Accelerating Factors and Innovative Environments

Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?

The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19

Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling

Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer

Prospects and Trends in the Brazilian Market for Biologically Sourced Products

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

DNA damage measurements within tissue samples with Repair Assisted Damage Detection (RADD)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance

Associations between DNA damage and PDL‐1 expression in ovarian cancer, a potential biomarker for clinical response

A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC)

The novel NSAID-derivative, MCI-030, prevents ovarian cancer in the egg-laying hen by increasing tumor cell apoptosis and decreasing beta-catenin and MAPK oncogenic signaling

Abstract B057: Racial disparity research in ovarian cancer: Evaluating race definition in differential gene expression

Abstract 1213: PDE10A as a novel target to suppress Wnt/β-catenin signaling and other oncogenic pathways in ovarian cancer

Abstract B31: Tumor-intrinsic B7-H3 regulates drug resistance, metabolism, and pathogenesis in ovarian cancer

Abstract POSTER-BIOL-1336: Investigating the role of phosphodiesterase 10A as a novel target in ovarian cancer

Abstract 5165: Novel RAS inhibitors DC070-547 and ADT-006 potently and selectively inhibit the growth of pancreatic tumor cells harboring constitutively activated RAS by blocking RAS-effector binding and signaling

Abstract 1937: Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors

Aktive Filter

Suchergebnisse filtern